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Background: Anticholinergic burden (ACB), is defined as the cumulative effect of
anticholinergic medication which are widely prescribed to older adults despite
increasing ACB being associated with adverse effects such as: falls, dementia and
increased mortality. This research explores the views of health care professionals
(HCPs) and patients on a planned trial to reduce ACB by stopping or switching
anticholinergic medications. The objectives were to explore the views of key
stakeholders (patients, the public, and HCPs) regarding the potential acceptability,
design and conduct of an ACB reduction trial.
Materials and Methods: We conducted qualitative interviews and focus groups with 25
HCPs involved in prescribing medication with anticholinergic properties and with 22
members of the public and patients who were prescribed with the medication. Topic
guides for the interviews and focus groups explored aspects of feasibility including: 1)
views of a trial of de-prescribing/medication switching; 2) how to best communicate
information about such a trial; 3) views on who would be best placed and preferred to
undertake such medication changes, e.g., pharmacists or General Practitioners (GPs)? 4)
perceived barriers and facilitators to trial participation and the smooth conduct of such a
trial; 5) HCP views on the future implementability of this approach to reducing ACB and 6)
patients’ willingness to be contacted for participation in a future trial. Qualitative data
analysis was underpinned by Normalization Process Theory.
Results: The public, patients and HCPs were supportive of an ACB reduction trial. There
was consensus among the different groups that key points to consider with such a trial
included: 1) ensuring patient engagement throughout to enable concerns/potential pitfalls
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misconceptions about the reasons for ACB reduction; and 3) provision of access to a point
of contact for patients throughout the life of a trial to address concerns; The HCPs in
particular suggested two more key points: 4) minimise the workload implications of any
trial; and 5) pharmacists may be best placed to carry out ACB reviews, though overall
responsibility for patient medication should remain with GPs.
Conclusion: Patients, the public and HCPs are supportive of trials to reduce ACB. Good
communication and patient engagement during design and delivery of a trial are essential
as well as safety netting and minimising workload.
Keywords: anticholinergics, deprescribing, polypharmacy, interviews, focus groups, qualitative research
INTRODUCTION
Background
Medications with anticholinergic properties are commonly
prescribed for a broad range of health conditions and are a
group of drugs that are particularly associated with adverse
events (Hanlon et al., 2020). Medications with anticholinergic
effects are used to treat a wide range of symptoms including
those affecting the urinary system and bladder, respiratory
system, mental health and certain diseases such as Parkinson’s
disease (Chew et al., 2008). Such medications are also frequently
prescribed for many chronic conditions including high blood
pressure, heart disease, hay fever and chronic lung disease.
Many different classes of medications including analgesic and
anti-inflammatory agents, anti-depressants, antidiabetic agents,
anti-infectives, antipsychotics, anxiolytics and sedative hypnotics,
cardiovascular medications, gastrointestinal and bowel agents,
anticonvulsants and urinary incontinence agents have
anticholinergic properties. Supplementary File two provides a list
of many commonly prescribed medications with anticholinergic
properties. They continue to be commonly prescribed in 20–30% of
older people despite their known association with negative health-
related outcomes (Singh, Lake and Furberg, 2008; Fox et al., 2014;
Myint et al., 2015; Richardson et al., 2015). The risk varies greatly
betweenmedications and accumulates with polypharmacy to create
a measurable level of anticholinergic burden (ACB). Increasing
ACB is associated with a range of adverse effects ranging from falls
through to cardiovascular events, dementia and death (Tune, 2001;
Hanlon et al., 2020). Research is urgently needed to aid clinicians in
measuring and reducing ACB in older people if we are to reduce the
associated adverse health outcomes. Policy documents have
highlighted risks of anticholinergic medications (Scottish
Government, 2018; Scottish Government, 2021) and promote
deprescribing efforts. However, the best approach to
deprescribing and the precise benefits or risks of deprescribing
interventions remain uncertain. Hence there is an urgent need for
clinical trial evidence, such as that from an ACB deprescribing/
medication switching trial, to inform deprescribing efforts in
clinical practice.
There are several scales that measure cumulative ACB (Neal
et al., 2017; Graves-Morris et al., 2020), however, a key
uncertainty is the question of how best to reduce ACB burden
at both population and individual patient level and importantly,
whether interventions to reduce ACB improve health. Any
intervention that aims to tackle prescribing practice in older
adults requires a multidisciplinary approach and any ACB
reduction trial will fall into the category of a complex
intervention as it will involve a number of different interacting
components, including influencing the behaviour and work of
health care professionals (HCPs) and patients (Craig et al., 2008).
A key aspect of intervention development is involving key
stakeholders, in this case, patients, the public and HCPs, from
the outset (O’Cathain et al., 2019). The literature on barriers and
facilitators to reducing ACB is scant (Stewart et al., 2019) and to
inform design of a proposed ACB reduction trial it will be
important to explore the views of such key stakeholders
regarding the potential acceptability and design of such an
intervention.
The objectives of this research were to explore the views of
such key stakeholders (i.e. patients, the public and HCPs)
regarding the potential acceptability, design and conduct of a
planned trial to reduce ACB by stopping or switching
anticholinergic medications. This qualitative research is an
essential step towards development of a definitive trial to
inform prescribing practice and policy.
Methods
Design
We conducted a qualitative study involving semi-structured
interviews and focus groups with healthcare professionals
working within two health boards in Scotland (NHS Greater
Glasgow & Clyde and NHS Grampian), and members of the
public and patients recruited from Glasgow, Edinburgh and the
West of Scotland, UK, between August 2019 and January 2020.
Participants
Eligible patients were those aged 65 years and over, who have
been prescribed anticholinergic medications and were able to
provide informed consent. Specifically, patients were eligible if
they took (or had taken in the past) two or more medications
from the list of medications with anticholinergic properties
provided in Supplementary File S2.
Eligible HCPs had to be employed as clinicians/doctors or
pharmacists within primary or secondary care within NHS
Greater Glasgow and Clyde or NHS Grampian, and whose
role involved providing care to patients aged 65 years and
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over. A full list of the roles of the HCPs interviewed is provided in
Table 1.
Ethical approval was obtained from both study centres before
starting public and patient recruitment and participants signed a
written informed consent before participation.
Recruitment
Members of the public were recruited from patient and carers’
support groups, including the Alliance Scotland, the Glasgow
Stroke Group, and NKS (Nari Kallyann Shangho). Potential
participants from all three groups received an e-mail
containing a flyer advertising the opportunity and listing the
eligibility criteria, please see the flyer in Supplementary File S2.
The Health and Social Care Alliance Scotland (the Alliance) is
Scotland’s national third sector intermediary for a range of health
and social care organisations. Their membership encompasses
over 3,000 national and local third sector organisations, associates
in the statutory and private sectors, disabled people, people living
with long-term conditions and unpaid carers. The Alliance
advertised through their mailing list of members to recruit
people who would be interested in participating in focus
groups about reducing ACB.
The Glasgow Stroke Research Group is a group of patients
who have experienced a stroke or who care for somebody who has
had a stroke. The group members are all interested in being
involved in PPI (Patient and Public Involvement in research) and
many of the medications prescribed for patients who have had a
stroke have anticholinergic properties. The Glasgow Stroke
Research Group is part of the NHS Research Scotland Stroke
Research Network. The group advertised through their mailing
list of members for anyone who would be interested in
participating in a focus group about reducing ACB.
NKS (Nari Kallyann Shangho) is a health advocacy group for
South Asian women and their families. NKS provide many
services including a carer’s forum, education and training
including English to Speakers of Other Languages (ESOL) and
informal computer classes, volunteering opportunities and work
placements, family support, home visits, and they also run a
nursery and after-school club. NKS advertised to their service
users for anyone interested in taking part in a focus group or
interview about reducing ACB.
Patient interviewees were also recruited from primary care
practices with the assistance of the NHS Research Scotland (NRS)
Primary Care Network. Eight men and fourteen women, aged
between 65 and 83, participated. Of these, twelve participated in
one of three focus groups, and ten participated in one-to-one
semi-structured qualitative interviews.
Recruitment of HCPs involved multiple strategies and
purposive sampling to ensure representation of HCPs from
differing geographical areas and health care settings
(i.e., primary and secondary care). General Practitioners (GPs),
geriatricians and pharmacists were recruited because they all
provide support to patients with chronic illness and are
involved in prescribing and medication management. All three
groups of professionals are also involved in de-prescribing efforts.
Potential participants were identified using the contacts and
networks of the Glasgow and Aberdeen research teams and the
NRS Primary Care Network. In total, twenty five participants
were included. Please see Table 1 for more information on
participant characteristics. Of these, fourteen participated in a
semi-structured qualitative interview and eleven participated in
one of three focus groups.
Procedures
We worked with support from contacts at the NRS Stroke Group,
NKS and the Alliance. We emailed these contacts an invitation
pack containing a printable flyer to advertise the upcoming focus
groups, a Participant Information Sheet and a letter of invitation.
Our contacts passed this information onto potential participants
and when they had gathered enough recruits organised times and
dates for the focus groups and interviews to take place with us.
For patients recruited through primary care, patients were sent
an invitation pack containing a letter of invitation, Participant
Information Sheet, expression of interest form and a stamped
addressed envelope. Those interested in participating in the study
were asked to return their expression of interest forms using the
stamped addressed envelopes provided. Potential participants
were then contacted by YC who provided further information
on the study and answered any questions they might have. If the
potential participant decided they would like to participate they
were asked about their medical conditions and medications and
agreed a convenient date, time and location for an interview or
focus group. The researcher (YC) made three attempts to contact
potential participants (at varying times and days), if no response
was received, another potential participant was selected.
Interviews were conducted until data saturation was reached
(i.e., no new themes within the data emerged) (Francis et al.,
2010). Before beginning each interview or focus group signed
informed consent was obtained. Interviews and focus groups were
recorded and transcribed verbatim for analysis.
HCPs who expressed an interest in participating were emailed
an invitation pack containing a letter of invitation, Participant
Information Sheet and expression of interest form.
Those expressing interest were emailed with details of the
date and time of the focus group and asked to confirm
acceptance. If no acceptance was received, a reminder email
and/or phone call was made. At the time of the interview or
focus group the researcher (YC) reconfirmed consent verbally
with the participants. Interviews and focus groups were
recorded and transcribed verbatim providing the data for
qualitative analysis.
TABLE 1 | Breakdown of HCP roles of participants.




Trainee GP 2 0
Geriatrician 4 4
Pharmacist 4 3
aNHS Greater Glasgow and Clyde is one of 14 regional NHS Boards in Scotland. It is the
largest health board in the UK.
bNHS Grampian provides NHS services for the half-million people who live in Grampian
and are overseen by one single NHS board.
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Each focus group began by welcoming participants and
making introductions. This was followed by a short
presentation from the research team to explain the purpose of
the focus group in more detail and to give a brief overview of
ACB. Participants were then given the opportunity to ask
questions before being invited to discuss their views about
ACB and de-prescribing or switching medications to reduce or
lessen ACB. The Topic Guide (which is included in
Supplementary File S3) was used to structure the discussion.
Development of Interview Schedule
In our interviews and focus groups, we used a Topic Guide which
explored several aspects of feasibility including: 1) views of a trial
of de-prescribing/medication switching; 2) how to best
communicate information about such a trial; 3) views on who
would be best placed and preferred to undertake such medication
changes; 4) perceived barriers and facilitators to trial participation
and the smooth conduct of such a trial; 5) HCP views on the
feasibility of this approach to ACB reduction and 6) willingness to
be contacted for participation in a future trial of this kind. The
Topic Guide is available in Supplementary File S3.
Data Analysis
Normalization Process Theory (NPT) was used to underpin the
analysis of interview and focus group transcripts. NPT explains
how the work of enacting an ensemble of tasks or practices is
accomplished through the operation of four mechanisms:
“coherence” (sense-making work); “cognitive participation”
(relationship work); “collective action” (enacting work); and
“reflexive monitoring” (appraisal work) (May and Finch, 2009;
May et al., 2009; Murray et al., 2010). We conceptualised the
reduction of ACB as a complex process comprising these four
types of mechanisms. Transcripts were imported into the
software package NVivo, version 11 (QSR International,
Melbourne, VIC, Australia). Following familiarisation with the
transcripts by YC, FM and CS, data were analysed using thematic
analysis; a method for searching, identifying and analysing
patterns of meaning or themes, in a dataset (Daly, Kellehear
and Gliksman, 1997; Braun and Clark, 2006). Thematic analysis
has six phases: familiarisation with data, generating initial codes,
searching for themes, reviewing themes, defining and naming
themes, and producing the report (Braun and Clark, 2006).
In our data analysis we followed a hybrid approach of
qualitative methods of thematic analysis, drawing on both
inductive (i.e., data-driven) and deductive (i.e., based on pre-
conceived ideas) approaches. This was an iterative and reflexive
process with the data collection and analysis being conducted
concurrently. Indeed, we chose thematic analysis among other
qualitative methods for its flexibility, while we position our study
within the social constructionist epistemological tradition,
according to which patterns of meaning and experience are
socially produced and reproduced (Braun and Clarke, 2006).
An initial thematic coding frame was developed. The themes
were based on NPT as per the topic guide. YC and CS coded all
the transcripts to produce a summary report and FM reviewed the
summary and discussed it with YC to check consistency with
the data.
Results
Our findings are presented under 6 key themes: 1) Sense-making
(patient and professional views of a trial of de-prescribing/
medication switching); 2) Relationship Work (patient and
professional views on how to best communicate information
about such a trial); 3) Enacting Work (patient and
professional views regarding who should undertake such
medication changes, for example, pharmacists or GPs?); 4)
Perceived barriers and facilitators to trial participation and the
smooth conduct of an ACB reduction trial; 5) Appraisal Work
(HCP and patient views on the future execution of this approach
to ACB reduction; and 6) Appraisal Work (Reflexive
monitoring): Public and patients’ willingness to be contacted
for participation in a future trial of this kind and general views
about a trial. These themes are described, and illustrative
quotations provided in the following section.
1) Sensemaking (coherence): patient and professional views of a
trial of de-prescribing/medication switching.
For patients, the sense-making or “coherence” work involved
learning about their conditions and medications, they described
getting information fromGPs, pharmacists andHCPs, as well as “Dr
Google” and friends and family members and of wanting a better
understanding of why they were taking different medications.
And when you, the internet is the worst thing ever, you
know you can go onto it and you look up all these things
and you can fit yourself into them (overtalk), well you
can fit your symptoms into them, right, and you can say:
“Oh I’ve got that” you know, “Oh I’ve got that as well”
right and you know you think you just had the cold
right, oh no it’s you know, you know it’s some dengue
fever or something, or other you know the Black Death
has come back.
AFG2M11, patient participant at focus group
Some patients read the information leaflet which came with
their medications thoroughly, others discarded it, preferring not
to learn about potential side-effects as they felt that knowing
might make them hesitant to take the medication. Patients who
were interviewed generally held positive views about the
possibility of running a trial of de-prescribing/medication
switching.
For HCPs, making sense of ACB first involved increasing their
awareness of the issues (knowledge and experience in dealing
with ACB varied depending on their roles). GPs described the
challenge of adding yet another factor that they needed to bear in
mind when prescribing as well as the problem of any ACB
reduction trial adding to an already heavy workload.
I think I pretty much covered that already in that it’s a
very good thing to do. I guess we would need to think
about the time factors, already there’s GP pressures,
we’ve got 10-min appointments, how would we do this
extra task? We’re constantly being asked from lots of
different professionals to do different tasks. We’ve got
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to have an (inaudible) care plan, got to do the
anticholinergic burden, we’ve got to do a
polypharmacy review, multi morbidity review, we’ve
got to do an annual reviews for every single condition
and that’s not even addressing any of the patient’s
agenda. It’s really difficult if you put all of this on
the doctor’s agenda because in 10 minutes we barely
have time to get through what the patients are worried
about. I think, yeah, it’s challenging.
Participant 9, GP in Aberdeen
HCPs believed that de-prescribing/switching would be good
for patients in the long run, and that findings from a trial could go
towards building the capacity of the health service to do this.
2) Relationship work (cognitive participation): patient and
professional views on how to best communicate
information about such a trial.
The work done to build and maintain the relationships
between patients and HCPs was considered vital by both
groups. Patients felt this could be facilitated by HCPs having
more time to discuss and explain medications and side-effects
with their patients.
“How do you talk to somebody in 10 min?” you go in
and you’re maybe wanting to tell them something right,
but you know, you end up coming out not having told
them, but that’s the thing, if they had a wee bit more
time but restrictions, you know if they had maybe 20-
min appointments right, but the numbers of GPs aren’t
sufficient for that.
AFG2M11, patient participant at focus group
Patients who were interviewed and who participated in focus
groups made a range of suggestions for how recruitment for a
future trial could be carried out, including letters from GPs, face-
to-face approaches at clinics, working together with voluntary
sector patient representative organisations and using
social media.
Well I actually think the Facebook messages are
good to be honest, you know I see quite a lot of
things on their trials, and I’ve gone for quite a few of
them, I’ve not been suitable for them because you
know, but you see things like: “Do you have diabetes
and high blood pressure?” for instance, “Would you
be prepared . . . ?” and that’s, I actually think those
are, I don’t, I know that interests me, I don’t know
how many other people it interests, but I’ve found
that quite a good way of contacting people. Yeah,
and probably the GP as well, if the GP said to me:
“Now, we’ve got a trial for exactly what you’re on,
would you be interested?” I mean I would say
immediately yes, I don’t know about other people.
AF15, patient interviewee
3) Enacting work (collective action) - Patient and Professional
views regarding who should undertake such medication
changes, for example, pharmacists or GPs.
It was clear that both patients and HCPs appreciated that any
intervention would need them to act differently. HCPs
suggested there would be a greater need for them to explain
and discuss the new way of working which would take time.
Some patients felt they should take a more active role in their
healthcare, but at the same time did not want to take up too
much of their GP’s time.
I think when you’re, when you’re reviewing someone’s
medications, depending on the person, there’s a lot of
work and time to be spent explaining: “Why are you on
this?” “What’s this doing for you?” “What are your
symptoms?” “This is what we’re trying to do,” I think
it’s just the main burden, just having time to do that,
and to do that, and to do that successfully with, with
patients on a kind of one-to-one because everyone’s
going to be on a different kind of cocktail of things.
TFGFP18, GP in Glasgow
HCPs mentioned that any intervention would involve
adapting to changes in roles and responsibilities, as for
example, pharmacists may take over prescribing
responsibilities from GPs. Most patients who were
interviewed and who participated in focus groups felt that
the GP should be the person to advise and carry out any
medication changes, however, patients who attended
practices which included a primary care pharmacist (who can
currently carry out reviews of medication in Scotland) said they
were comfortable with a pharmacist undertaking medication
changes.
I would appreciate either a GP review, or a pharmacy
review, and I’mnot knocking the nurse right, but I don’t
think the nurse has enough in-depth understanding of
medication, you know because, pharmacy it’s about
5 years right talking about interaction of drugs and
that, medicine it’s 5 years and there’s a wee bit
pharmacology in it as well, whereas nursing there’s
not really any pharmacology in their training right,
so that’s just my personal view you know.
AFG2M11, participant at focus group
The HCPs interviewed differed with each other in their views
about who should undertake medication changes. Pharmacists
interviewed believed that they were very well equipped to do it,
and that pharmacists carrying out this work would create a benefit to
the patients and would also reduce the GPs’ workload. However,
some pharmacists believed that overall responsibility for the patient
and the medication prescribed should remain with the GP.
Well I think pharmacists, like I think we’re very well
equipped to do it, to, to manage it and particularly in the
kind of the new GP contract when there’s going to be a
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lot more of us about and a lot more of us in GP practices
you know I think that would be a good role for us . . . so
however I guess the overall responsibility kind of lies
with the, you know I would say the overall responsibility
is, it’s the kind of ethos that it lies with the kind of senior
whatever person, like it would be the GP really.
PP6, Glasgow pharmacist
GPs who were interviewed stressed their lack of spare time during
the working day and an existing heavy workload, meaning that it
would not be sustainable for them to review medication to look for
anticholinergic medications on top of their existing work. GPs
supported the idea of pharmacists carrying out changes in
medication for patients, so long as the system worked in such a
way that pharmacists doing reviews did not add to theGPs’workload.
4) Perceived barriers and facilitators to trial participation and the
smooth conduct of an ACB reduction trial.
For patients and the public, there were several potential
barriers to participating in a trial. Firstly, some expressed the
view that they would be wary of a return of symptoms if they
changed or stopped medication (Coherence). This was especially
true for patients who were taking anti-depressant medication,
which takes some time to begin working after starting to take it.
Secondly, some patients interviewed were sceptical of the
motivations behind switching medications and expressed
suspicions that it was a cost-saving exercise rather than a
change for their benefit (Coherence).
Not really, I would be prepared if they, if they could give
me a good argument for changing then I would
definitely do it, if they were to say: “I want to, I want
you to try this tablet because I think you’ll have fewer
side effects” then I would definitely give it a go yes.
AF15, patient participant at focus group
For HCPs, themain barrier to reducing ACBwas insufficient time
in a GP appointment to talk to a patient in-depth about medication,
especially for patients with multiple long-term conditions. GPs said
that it was already difficult in the short time that they had to
communicate potential future risks (Collective Action).
The strongest facilitator to participating in a trial for patients/
public and HCPs was that there was a desire from both groups to de-
prescribe/take fewer tablets (Coherence). The HCPs interviewed
agreed that patients were amenable to change if it was explained
and discussed with them in detail, and their concerns were heard.
You could try and couch it in quite positive terms,
sometimes you do manage to get people off things so
don’t want to be too negative about it.
TFGFP18, GP in Glasgow
5) Appraisal Work (Reflexive monitoring): HCP and patient
views on the future implementability of this approach to
ACB reduction.
Many of the members of the public and patients interviewed
stated that, for a pilot study to be successful, they would expect
and want to be closely monitored during it and have speedy
access to a contact person with whom they could raise any
concerns they might have.
You’d like to have somebody to right just say it was you I
had your, like, number, and I could phone up and say:
“Look it’s (Name) here I’m shaking with this” [overtalk],
that’s not for you if you could have a link, a communication
link that you could raise any concerns that would be, that
would be acted on, you know and you could give you know
appropriate guidance in that respect.
P2, Patient participant at focus group
TheHCPs interviewed had some suggestions about how ACB
could be reduced. They emphasised the need for a usable scoring
system, which would be a useful guide to the ACB, and which
could be incorporated into existing Information Technology
(IT) systems. Any IT system would need to provide information
about the ACB score in a useful format; but should avoid
causing “pop-up fatigue” i.e., too many irrelevant alerts
causing the users to ignore them. HCPs also stressed the
importance of long-term follow up, as without it they could
not assess if de-prescribing worked.
Some HCPs expressed the view that in some cases, there are
no alternatives to an anticholinergic medication which would
work as well, for example, one focus group discussed the
difficulties with avoiding ACB when prescribing pain-
relieving medication in cases where paracetamol does not
give sufficient relief from symptoms. GPs also discussed how
patients sometimes had the expectation that there should be “a
pill for every ill,” making it difficult to get the balance right.
HCPs also spoke about previous experiences of de-prescribing
initiatives which did not succeed or which increased their
workload (Reflexive Monitoring).
6) Appraisal Work (Reflexive monitoring). Public and patients’
willingness to be contacted for participation in a future trial of
this kind and general views about a trial.
Most members of the public and patients interviewed said that
they were willing to be contacted about future participation in a
trial and were generally positive about the idea of examining
prescribing in this way.
The findings are summarised in Table 2.
DISCUSSION
Our study highlights that members of the public, patients and
HCPs are all open to the idea of ACB reduction through
interventions that promote de-prescribing or medication
changes. It was clear that patients and members of the public
were eager to better understand what different medications were
for and why they should be taking them. Poor understanding of
treatments is a longstanding problem in healthcare (Browne et al.,
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2014). However, while the key stakeholders were supportive of
the idea of the future trial there were several caveats and
recommendations. The participating members of the public
and patients were clear that PPI would be essential from the
outset. They thought that it would be essential to ensure patient
engagement from the beginning to enable concerns and potential
pitfalls of anticholinergic de-prescribing to be addressed from the
outset. They emphasised the importance of clear communication
so that patients involved in any trial have a very clear
understanding of the rationale and aims of a trial to minimise
the potential for misconceptions about the reasons for ACB
reduction. They also suggested it would be important to provide
access to a point of contact for patients throughout the life of a trial
to address queries or concerns.While HCPswere generally positive
about the idea of de-prescribing or medication switching it was
clear that taking steps to minimise the workload implications of
any ACB reduction trial would be important. GPs emphasised that
their workloads were heavy and time constraints would pose a
major barrier to the potential success of any de-prescribing
intervention. GPs suggested that more effective utilisation of
Information Technology (IT) systems might make the work of
de-prescribing easier. There was a consensus that pharmacists are
TABLE 2 | Summary of findings from interviews and focus groups.
1) Sense-making (coherence)
Patient and professional views of a trial of de-prescribing/switching
Patients • Learning about their conditions and medications
• Sourcing information from HCPs and the internet
• Fear of learning too much
• Generally positive about running de-prescribing/switching trial
HCPs • Varied knowledge of ACB depending on role
• GPs wary of adding to already heavy workload
• General positive attitude towards de-prescribing/switching
2) Relationship work (cognitive participation)
Patient and professional views on how to best communicate information about such a trial
Patients • HCPs need to take more time to explain medications and side-effects
HCPs —
3) Enacting work (collective Action)
Patient and professional views regarding who should undertake such medication changes, for example, pharmacists or GPs?
Patients • Intervention would mean that they would need to take a more active role in their healthcare
• Patients who had experienced prescribing pharmacists were happy for pharmacists to prescribe
HCPs • Would need more time with patient appointments to discuss the new way of working
• Change in roles required i.e. widen prescriber role
• Pharmacists to prescribe but overall responsibility to remain with GP
• GPs wary of adding to already heavy workload
4) Barriers and facilitators
Perceived barriers and facilitators to trial participation and the smooth conduct of an ACB reduction trial
Barriers
Patients • Wary of symptoms returning (especially depression)
• Sceptical of motivations. Suspicious it’s cost-saving
HCPs • Insufficient time in patient appointments for discussion
Facilitators
Patients • Desire to take fewer tablets
HCPs • Desire to de-prescribe
• Patients amenable to change if sufficient time take to explain to them and hear their concerns
5) Appraisal work (reflexive monitoring)
HCP and patient views on the future implementability of this approach to ACB reduction
Patients • Wanted trial participants closely monitored
HCPs —
6) Appraisal work (reflexive monitoring)
Public and patients’ willingness to be contacted for participation in a future trial of this kind and general views about a trial
Patients • Public and patients’ were willing to be contacted about participation in a future trial of this kind and made suggestions
about how best to recruit participants for such a trial
HCPs —
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best placed to carry out ACB reviews, though overall responsibility
for patient medication should remain with the GP.
While there is a broad range of literature addressing barriers
and facilitators to de-prescribing (Anderson et al., 2014; Luymes
et al., 2016, Reeve et al., 2013) there is little focused specifically on
de-prescribing of anticholinergic medication (Kouladjian et al.,
2016; Gnjidic et al., 2010). The existing qualitative work exploring
barriers and facilitators to ACB reduction have only involved
HCPs (Kouladjian et al., 2016; Gnjidic et al., 2010) and to the best
of our knowledge, there have been no studies involving patients
or members of the public that have explored the issue of
anticholinergic de-prescribing. The work with HCPs did show,
as in our study, that good communication with patients and other
HCPs would be important and that assigning responsibility for
prescribing decisions to one named individual would be helpful
(Kouladjian et al., 2016; Gnjidic et al., 2010). This work showed
that resource constraints were also an issue, and the wider de-
prescribing literature confirms time constraints can be a barrier to
de-prescribing (Anderson et al., 2014). Our work resonates with
the wider de-prescribing literature where patients have been
involved (Steinman and Reeve, 2020) which emphasises the
importance of engaging with patients in the de-prescribing
process, ensuring they understand “why” a medication should
be switched or stopped. Our findings that patients were often
unclear of the purpose of different medications resonates with
an extensive literature that highlights how patients and
caregivers often have inadequate understanding of
medications, their side effects, and limitations (Browne et al.,
2014) and indeed often turn to the internet to address
information gaps (Fox and Duggan, 2013). Our work is novel
in that it explicitly sought views on the design of a proposed
ACB reduction trial but suggests any intervention will be more
likely to be successful if patients and their supporters better
understand the reasons for treatments. Thus, any future trial
will need to help people better understand the pros and cons of
different medications. Making such information easily
comprehensible will be an important issue for any future de-
prescribing interventions.
STUDY LIMITATIONS/STRENGTHS
Our study has certain limitations. The study was conducted in
Scotland, which provides universal access to healthcare, and
thus these qualitative findings may not be generalisable to other
healthcare contexts. While we did include non-English speakers,
most of our sample were Caucasian, so it will be important to
conduct future work with other ethnic groups. A clear strength
of the study is the involvement of members of the public,
patients, and HCPs as well as our use of a robust theoretical
framework, NPT, to help us conceptualise our data.
CLINICAL IMPLICATIONS
While our findings will primarily be used to feed into the design
of a proposed ACB reduction trial. Our study suggests that
members of the public, patients and HCPs are all open to the
idea of ACB de-prescribing. Members of the public and patients
were clear that they would like to increase their understanding of
the medications that they are prescribed and that they would be
open to de-prescribing if it was viewed as helpful to their
wellbeing. Good communication is definitely a key issue to
underpin de-prescribing or medication switching initiatives.
However, time constraints are a major barrier to de-
prescribing, and therefore if clinicians and policy makers wish
to promote de-prescribing then structural changes to the way we
deliver health care services, whether through enhanced use of IT
or other mechanisms will be required to enable HCPs, to have the
capacity to undertake such work.
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